Article

FDA Seeks More Authority Over Compounding Pharmacies

The Food and Drug Administration said its authority over compounding pharmacies is limited and needs to be strengthened in the wake of a multistate meningitis outbreak caused by tainted steroid injections produced by a pharmacy in Massachusetts.

The FDA has come under scrutiny for its oversight of the New England Compounding Center, the Framingham, Mass.-based compounding pharmacy that is responsible for distributing contaminated vials of preservative-free methylprednisolone acetate.

Read the full story:http://bit.ly/XF0gF0

Source: ModernHealthcare.com

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Steven Daveluy, MD, dermatologist, Wayne State University
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Emilie Aschenbrenner, PharmD, BCOP, Froedtert Health and the Medical College of Wisconsin
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo